The CorDx COVID-19 Ag Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus
The test is designed for non-prescription home use and features a 10-minute time to result. (Credit: Mufid Majnun on Unsplash)
CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and other medical devices, recently received approval-for-use in Singapore for its COVID-19 Ag Test. The test is designed for non-prescription home use and features a 10-minute time to result.
The approval was granted by Singapore’s Health Sciences Authority (HSA), a multi-disciplinary agency responsible for applying medical, pharmaceutical, and scientific expertise to protect and advance public health and safety in the country.
The CorDx COVID-19 Ag Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus.
“We are thrilled to receive approval for our COVID-19 Ag Test in Singapore and are committed to providing safe and effective solutions for the health and well-being of individuals in the region,” said Jeff Yufeng Li, CorDx’s founder & CEO. “This marks a significant milestone in our mission to help combat the global pandemic and bring an end to the suffering caused by COVID-19.”
On January 12, 2023, CorDx announced a new Asia-Pacific (APAC) business development center in Singapore, as well as plans for an R&D laboratory there.
Source: Company Press Release